Evidence map›Paper›PMID 27100399›Full record

Trial reportPloS one2016

The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial.

Ruben Poesen, Pieter Evenepoel, Henriette de Loor, Jan A Delcour, Christophe M Courtin, Dirk Kuypers, Patrick Augustijns, Kristin Verbeke, Björn Meijers

3 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 62 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 7 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02141815 nacompletednot on this map

The Effect of Arabinoxylan-oligosaccharides (AXOS) on Intestinal Generation of Microbial Metabolites in Chronic Kidney Disease

TypeinterventionalSponsorUniversitaire Ziekenhuizen KU LeuvenRan2014 to 2016Enrolled40ConditionsChronic Kidney DiseaseArmsArabinoxylan-oligosaccharides, Maltodextrine
NCT03770611 naunknown statusnot on this mapstarted 2019, after this paper: background citation

Effect of a Nutritional Supplement of Probiotics and/or Prebiotics vs Placebo on Serum Concentrations of Uremic Toxins and Inflammatory Cytokines in Automated Peritoneal Dialysis Patients.

TypeinterventionalSponsorUnidad de Investigacion Medica en Enfermedades RenalesRan2019 to 2020Enrolled112ConditionsEnd Stage Renal Failure on DialysisArmsProbiotic, Prebiotic, Symbiotic, Placebo
NCT04527640 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Effects of Synbiotics Supplementation on the Concentration of the Uremic Toxin Indoxyl Sulfate, Symptoms of Constipation, and Constipation-related Quality of Life in End-stage Renal Disease Patients Undergoing Hemodialysis

TypeinterventionalSponsorIndonesia UniversityRan2020 to 2021Enrolled60ConditionsConstipation, End Stage Renal Disease on DialysisArmsSynbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg, Placebo
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 7 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2021
    Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ruben PoesenDepartment of Microbiology and Immunology, Division of Nephrology, University Hospitals Leuven, B-3000, Leuven, Belgium.ORCID http://orcid.org/0000-0002-9534-4919
Pieter EvenepoelDepartment of Microbiology and Immunology, Division of Nephrology, University Hospitals Leuven, B-3000, Leuven, Belgium.
Henriette de LoorDepartment of Microbiology and Immunology, Division of Nephrology, University Hospitals Leuven, B-3000, Leuven, Belgium.
Jan A DelcourDepartment of Microbial and Molecular Systems, Centre for Food and Microbial Technology, University of Leuven, B-3000, Leuven, Belgium.
Christophe M CourtinDepartment of Microbial and Molecular Systems, Centre for Food and Microbial Technology, University of Leuven, B-3000, Leuven, Belgium.
Dirk KuypersDepartment of Microbiology and Immunology, Division of Nephrology, University Hospitals Leuven, B-3000, Leuven, Belgium.
Patrick AugustijnsDepartment of Pharmaceutical and Pharmacological Sciences, Drug Delivery and Disposition, University of Leuven, B-3000, Leuven, Belgium.
Kristin VerbekeLeuven Food Science and Nutrition Research Centre (LFoRCe), University of Leuven, B-3000, Leuven, Belgium.
Björn MeijersDepartment of Microbiology and Immunology, Division of Nephrology, University Hospitals Leuven, B-3000, Leuven, Belgium.
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe colonic microbial metabolism is a key contributor to uremic retention solutes accumulating in patients with CKD, relating to adverse outcomes and insulin resistance. Whether prebiotics can reduce intestinal generation of these microbial metabolites and improve insulin resistance in CKD patients not yet on dialysis remains unknown. We performed a randomized, placebo-controlled, double-blind, cross-over study in 40 patients with eGFR between 15 and 45 ml/min/1.73 m2. Patients were randomized to sequential treatment with prebiotic arabinoxylan oligosaccharides (AXOS) (10 g twice daily) and maltodextrin for 4 weeks, or vice versa, with a 4-week wash-out period between both intervention periods. Serum levels and 24h urinary excretion of p-cresyl sulfate, p-cresyl glucuronide, indoxyl sulfate, trimethylamine N-oxide and phenylacetylglutamine were determined at each time point using liquid chromatography-tandem mass spectrometry. In addition, insulin resistance was estimated by the homeostatic model assessment (HOMA-IR). A total of 39 patients completed the study. We observed no significant effect of AXOS on serum p-cresyl sulfate (P 0.42), p-cresyl glucuronide (P 0.59), indoxyl sulfate (P 0.70) and phenylacetylglutamine (P 0.41) and a small, albeit significant decreasing effect on serum trimethylamine N-oxide (P 0.04). There were neither effect of AXOS on 24h urinary excretion of p-cresyl sulfate (P 0.31), p-cresyl glucuronide (P 0.23), indoxyl sulfate (P 0.87) and phenylacetylglutamine (P 0.43), nor on 24h urinary excretion of trimethylamine N-oxide (P 0.97). In addition, we observed no significant change in HOMA-IR (P 0.93). In conclusion, we could not demonstrate an influence of prebiotic AXOS on microbiota derived uremic retention solutes and insulin resistance in patients with CKD not yet on dialysis. Further study is necessary to elucidate whether prebiotic therapy with other characteristics, higher cumulative exposure or in different patient populations may be of benefit.

trial registrationClinicaltrials.gov NCT02141815.

Indexed as

AgedCross-Over StudiesDouble-Blind MethodFemaleHemodiafiltrationHumansMaleMicrobiotaOligosaccharidesPrebioticsRenal DialysisRenal Insufficiency, ChronicUreaUremiaXylansarabinoxylanOligosaccharidesPrebioticsUreaXylans

Identifiers

PMID27100399
PMCPMC4839737
OpenAlexW2338541240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.